quinazolines has been researched along with 2,6-diaminopurine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holý, A; Kmonícková, E; Potmesil, P; Zídek, Z | 1 |
| Froeyen, M; Kaptein, S; Neyts, J; Rozenski, J; Saudi, M; Van Aerschot, A; Venkatesham, A | 1 |
2 other study(ies) available for quinazolines and 2,6-diaminopurine
| Article | Year |
|---|---|
Purine P1 receptor-dependent immunostimulatory effects of antiviral acyclic analogues of adenine and 2,6-diaminopurine.
Topics: 2-Aminopurine; Adenine; Adjuvants, Immunologic; Animals; Anti-HIV Agents; Caffeine; Cell Survival; Cells, Cultured; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Dihydropyridines; Dose-Response Relationship, Drug; Female; Flavins; Humans; Interleukin-10; Lipopolysaccharides; Macrophage Inflammatory Proteins; Macrophages; Mice; Mice, Inbred C57BL; Molecular Structure; Organophosphonates; Purinergic P1 Receptor Antagonists; Quinazolines; Receptors, Purinergic P1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Theophylline; Triazoles; Tumor Necrosis Factor-alpha | 2006 |
Aminopurine and aminoquinazoline scaffolds for development of potential dengue virus inhibitors.
Topics: 2-Aminopurine; Antiviral Agents; Dengue Virus; Drug Design; Molecular Docking Simulation; Protein Conformation; Quinazolines; Viral Nonstructural Proteins | 2017 |